KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Total Non-Current Liabilities (2018 - 2025)

Vir Biotechnology's Total Non-Current Liabilities history spans 8 years, with the latest figure at $203.4 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 9.33% year-over-year to $203.4 million; the TTM value through Dec 2025 reached $203.4 million, down 9.33%, while the annual FY2025 figure was $203.4 million, 9.33% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $203.4 million at Vir Biotechnology, up from $189.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $867.2 million in Q1 2022 and bottomed at $189.2 million in Q3 2025.
  • The 5-year median for Total Non-Current Liabilities is $314.8 million (2021), against an average of $390.8 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 367.39% in 2021 before it crashed 66.17% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $519.9 million in 2021, then surged by 37.15% to $713.0 million in 2022, then plummeted by 57.52% to $302.9 million in 2023, then fell by 25.91% to $224.4 million in 2024, then decreased by 9.33% to $203.4 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Total Non-Current Liabilities are $203.4 million (Q4 2025), $189.2 million (Q3 2025), and $211.4 million (Q2 2025).